Who Paid My Doc
Peter Monteleone
Interventional Cardiology Kyle, TX Medical Doctor
NPI 1164625760 CMS profile 7267
1180 Seton Pkwy, Suite 450, Kyle, TX 78640
General payments
$461,389
Research payments
$56,212
Ownership & investment interest
$0
Research they led as principal investigator
$679,140
Through program year 2025, Peter Monteleone of Kyle, TX is reported in the CMS Open Payments database as having received $461,389 across 706 general payments and $56,212 in research payments paid to them. Separately, studies naming them as principal investigator received $679,140 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $99,321 | 111 | |
| 2024 | General | $111,311 | 107 | |
| 2023 | General | $90,435 | 137 | |
| 2023 | Research | $2,600 | 1 | |
| 2022 | General | $68,155 | 142 | |
| 2022 | Research | $23,200 | 1 | |
| 2021 | General | $25,380 | 32 | |
| 2021 | Research | $30,412 | 4 | |
| 2020 | General | $20,860 | 37 | |
| 2019 | General | $45,928 | 140 |
Beside peers
- Peter Monteleone
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Peter Monteleone were reported at $99,321. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Peter Monteleone | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $45,928 | $1,097 | $329–$3,048 | $163 |
| 2020 | $20,860 | $473 | $161–$1,480 | $114 |
| 2021 | $25,380 | $677 | $233–$1,827 | $132 |
| 2022 | $68,155 | $978 | $333–$2,724 | $149 |
| 2023 | $90,435 | $1,136 | $382–$2,986 | $160 |
| 2024 | $111,311 | $1,181 | $395–$3,326 | $164 |
| 2025 | $99,321 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
1,583
Drug cost
$194,197
Branded share of claims
19.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 99 | $87,868 | |
| Repatha Sureclick Evolocumab | Brand | 43 | $44,279 | |
| Entresto Sacubitril/Valsartan | Brand | 13 | $24,747 | |
| Xarelto Rivaroxaban | Brand | 17 | $23,838 | |
| Rosuvastatin Calcium | Generic | 239 | $2,021 | |
| Atorvastatin Calcium | Generic | 185 | $1,716 | |
| Metoprolol Succinate | Generic | 134 | $1,624 | |
| Ezetimibe | Generic | 48 | $1,395 | |
| Nitroglycerin | Generic | 71 | $1,071 | |
| Carvedilol | Generic | 137 | $1,011 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 68 billing codesPaid by Medicare
$82,382
Medicare patients
283
Services billed
918
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 64% | |
| Arthritis | 44% | |
| Diabetes | 35% | |
| Atrial fibrillation | 33% | |
| Heart failure | 31% | |
| Chronic kidney disease | 25% | |
| Depression | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
712 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Texas
Juan Granada
Interventional Cardiology · Houston, TX
Vamsi Krishna
Interventional Cardiology · Kyle, TX
Jeffrey Carr
Interventional Cardiology · Tyler, TX
John Isaac
Interventional Cardiology · Houston, TX
Robert Chilton
Interventional Cardiology · San Antonio, TX
Sameh Sayfo
Interventional Cardiology · Plano, TX
Related records
Interventional Cardiology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.